DOSE OF REALITY: BIG PHARMA’S PATENT THICKETS COST PATIENTS AND TAXPAYERS BILLIONS IN LOST SAVINGS EACH YEAR
Jan 26, 2023
New Matrix Global Advisors Report Shines Light on Cost of Big Pharma’s… Read More
© 2024 CSRXP- All Rights Reserved
Dose of Reality
DOSE OF REALITY: BREAKING DOWN BIG PHARMA’S YEAR OF BAD BEHAVIOR IN 2022
Dec 28, 2022
Get the Facts on Big Pharma’s Year of Out-of-Control Launch Prices… Read More
DOSE OF REALITY: NEW STUDY UNDERSCORES BIG PHARMA’S PRICING PRACTICES ARE ABOUT PROFITS, NOT VALUE FOR PATIENTS
Nov 1, 2022
JAMA Analysis Finds No Correlation Between Cancer Drug Prices and… Read More
DOSE OF REALITY: NEW STUDY DEBUNKS BIG PHARMA CLAIMS THAT HIGH PRESCRIPTION DRUG PRICES ARE TIED TO R&D INVESTMENTS
Sep 29, 2022
JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s… Read More
DOSE OF REALITY: BIG PHARMA’S PRICING PRACTICES DRIVE CRISIS OF AFFORDABILITY FOR CANCER PATIENTS
Sep 20, 2022
Shining a Light on How Big Pharma is Rapidly Increasing Prices on Oncology… Read More
DOSE OF REALITY: REPORT FINDS RX SPENDING CONTINUED TO RISE AS BIG PHARMA MAINTAINED BUSINESS-AS-USUAL APPROACH TO PRICE-GOUGING
Sep 1, 2022
Analysis Highlights How Escalating Prescription Drug Costs, Driven By Big… Read More
DOSE OF REALITY: PATENT HEARINGS OFFER OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTI-COMPETITIVE PRACTICES
Jun 22, 2022
Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives… Read More
DOSE OF REALITY: BIG PHARMA TARGETS MERGERS AND ACQUISITIONS TO KEEP PRICES HIGH, EXTEND MONOPOLIES AND BOOST PROFITS
Jun 13, 2022
FTC Workshop Can Highlight How Brand Name Drug Companies Employ… Read More
DOSE OF REALITY: SENATE COMMERCE HEARING OPPORTUNITY FOR LAWMAKERS TO HOLD BIG PHARMA ACCOUNTABLE
May 3, 2022
Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious… Read More
DOSE OF REALITY: NEW STUDY FINDS ONE THIRD OF SENIORS DO NOT FILL PRESCRIPTIONS FOR HIGH-PRICE DRUGS USED TO TREAT SERIOUS CONDITIONS
Apr 6, 2022
Academic Study Underscores How Big Pharma’s Price-Gouging on Treatments for… Read More
DOSE OF REALITY: LAWMAKERS MUST HOLD BIG PHARMA ACCOUNTABLE IN SENATE FINANCE HEARING
Mar 14, 2022
Congress Can Refocus Attention on Market-Based Solutions to Crack Down on… Read More
DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION
Jan 19, 2022
Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for… Read More